Phase 3 of the DESTINY-Breast03 randomized trial compared the efficacy of T-DM1 to T-DXd in HER2-postive breast cancer patients, and individuals treated with T-DXd had higher progression-free survival (PFS) and OS rate [159]. Here, ERBB2 is linked to breast carcinoma.